pembrolizumab
merck
['lymsm', 'lymphoma', 'pembro']
#eha2022 | luciana vinti provided results from the keynote-667 study, investigating pembro plus chemo in patients with nd chl. treatment was well tolerated and resulted in 68% of patients having a pet-negative response at end of chemo, and being spared rt #lymsm #lymphoma 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm